Symptomfri eller mild symptomatisk NYHA klasse I- II objektive fund blev observeret hos 3, 0% af patienterne i Herceptin- armen, sammenlignet med 0, 5% af patienterne i kontrolarmen.
Asymptomatic or mildly symptomatic NYHA class I – II events were observed in 3.0% of patients in the Herceptin arm compared to 0.5% of patients in the observation arm.